<i>CRLF2</i> -rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy
Sara Silbert(National Institutes of Health), Nirali N. Shah(National Institutes of Health), Constance M. Yuan(National Cancer Institute), Anupam Verma(Primary Children's Hospital), Ilan Kirsch(Adaptive Biotechnologies (United States)), Sandra D. Bohling(Seattle Children's Hospital), Samantha Scanlon(University of Washington), Adam J. Lamble(Seattle Children's Hospital), Karen M. Chisholm(Seattle Children's Hospital), Evrim Türkbey(National Institutes of Health Clinical Center), Raul C. Braylan(Center for Cancer Research), Haneen Shalabi(Center for Cancer Research), Alyssa Doverte(National Institutes of Health), Mark A. Ahlman(Augusta University), Nisha Patel(National Institutes of Health), Kasey J. Leger, Murat Alp Öztek(University of Washington), Hao‐Wei Wang(Fu Jen Catholic University), Mike LaLoggia(Lake Erie College of Osteopathic Medicine), Alexandra E. Kovach(University of Southern California), Jake Wellek(National Cancer Institute), Brent L. Wood(University of Southern California)
Cited by 8
Related Papers
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744